Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methylnaltrexone in opioid-induced constipation
NCT00936884Phase 3Completed
- Sponsor
- Valeant Pharmaceuticals
- Start
- Jul 2009
- Primary completion
- Nov 2013
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of methylnaltrexone in opioid-induced constipation (OIC) (3 arms), sponsored by Valeant Pharmaceuticals. Primary endpoints: Proportion of Subjects Having a Rescue-free Bowel Movement (RFBM) Within 4 Hours After the First Injection and Proportion of Subjects Having a Rescue-free Bowel Movement (RFBM) Within 4 Hours After Each Dose During Double-blind Period. Started Jul 2009; status: completed.
02
Drugs
methylnaltrexone
03
Conditions
opioid-induced constipation (OIC)
Beyond the preview
Go deeper on NCT00936884.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00936884.